SG Americas Securities LLC Sells 4,586 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

SG Americas Securities LLC cut its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 25.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 13,699 shares of the specialty pharmaceutical company’s stock after selling 4,586 shares during the quarter. SG Americas Securities LLC’s holdings in Collegium Pharmaceutical were worth $392,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the company. Nisa Investment Advisors LLC increased its holdings in shares of Collegium Pharmaceutical by 14.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock valued at $71,000 after acquiring an additional 316 shares in the last quarter. TD Private Client Wealth LLC raised its stake in shares of Collegium Pharmaceutical by 39.5% in the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock worth $66,000 after purchasing an additional 483 shares during the last quarter. Foundry Partners LLC grew its holdings in Collegium Pharmaceutical by 3.3% during the third quarter. Foundry Partners LLC now owns 15,781 shares of the specialty pharmaceutical company’s stock valued at $610,000 after purchasing an additional 509 shares during the period. CWM LLC lifted its position in shares of Collegium Pharmaceutical by 97.5% in the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock worth $58,000 after buying an additional 736 shares in the last quarter. Finally, GAMMA Investing LLC raised its holdings in shares of Collegium Pharmaceutical by 124.5% in the third quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock worth $55,000 after buying an additional 792 shares during the period.

Insider Transactions at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 27,500 shares of the firm’s stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $33.04, for a total value of $908,600.00. Following the transaction, the executive vice president now directly owns 119,184 shares of the company’s stock, valued at approximately $3,937,839.36. This trade represents a 18.75 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 3.98% of the stock is owned by insiders.

Collegium Pharmaceutical Stock Performance

NASDAQ COLL opened at $31.20 on Tuesday. The company has a fifty day simple moving average of $31.02 and a 200 day simple moving average of $34.18. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The company has a market cap of $1.01 billion, a P/E ratio of 13.45 and a beta of 0.82. Collegium Pharmaceutical, Inc. has a 12-month low of $28.39 and a 12-month high of $42.29.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. StockNews.com cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 23rd. Piper Sandler reaffirmed a “neutral” rating and issued a $37.00 target price on shares of Collegium Pharmaceutical in a research note on Friday, October 11th. Needham & Company LLC raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a research report on Friday, January 10th. Finally, HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Collegium Pharmaceutical in a research note on Friday, January 10th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, Collegium Pharmaceutical has a consensus rating of “Moderate Buy” and an average price target of $43.80.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.